Screening for neuropathic pain in patients with sickle cell disease: Is a single assessment scale sufficient?

7Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The objectives of this study were to delineate the clinical-epidemiological profile of patients with neuropathic pain (NP) in the groups of SCD patients, from each of the three questionnaires used DN-4, painDETECT - PDQ, LANSS and to compare these three questionnaires in NP evaluation in SCD carriers. This cross-sectional study evaluated 83 patients with symptomatic SCD, aged 14 years or older. Clinical and laboratory data were extracted from the patients' charts and from information obtained from the patients during the interview before the application of the questionnaire. The calculations were performed using the statistical software Epi InfoTM 7. Pearson's correlation coefficient was used to compare the neuropathic pain evaluation scales with the software BioEstat 5.3. Results: The use of two or more questionnaires may increase the suspicion of NP in patients with SCD and, with a confirmed diagnosis, adequate treatments will benefit patients.

Cite

CITATION STYLE

APA

Antunes, F. D., Silva Junior, C. L., Cerqueira, K. S., Do Livramento Faro, M., & Cipolotti, R. (2019). Screening for neuropathic pain in patients with sickle cell disease: Is a single assessment scale sufficient? Orphanet Journal of Rare Diseases, 14(1). https://doi.org/10.1186/s13023-019-1082-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free